Intensity Therapeutics In... (INTS)
Intensity Therapeutics Statistics
Share Statistics
Intensity Therapeutics has 15.1M shares outstanding. The number of shares has increased by 10.18% in one year.
| Shares Outstanding | 15.1M |
| Shares Change (YoY) | 10.18% |
| Shares Change (QoQ) | 9.68% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 8.22M |
| Failed to Deliver (FTD) Shares | 57 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 44.28K, so 0.29% of the outstanding shares have been sold short.
| Short Interest | 44.28K |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.58% |
| Short Ratio (days to cover) | 3.05 |
Valuation Ratios
The PE ratio is -7.01 and the forward PE ratio is -1.95. Intensity Therapeutics's PEG ratio is -0.05.
| PE Ratio | -7.01 |
| Forward PE | -1.95 |
| PS Ratio | 0 |
| Forward PS | 0.6 |
| PB Ratio | 5.61 |
| P/FCF Ratio | -10.25 |
| PEG Ratio | -0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Intensity Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.91, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.91 |
| Quick Ratio | 3.91 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.19 |
| Cash Flow / Debt | -45.6 |
| Interest Coverage | -27.28 |
Financial Efficiency
Return on equity (ROE) is -0.8% and return on capital (ROIC) is -62.45%.
| Return on Equity (ROE) | -0.8% |
| Return on Assets (ROA) | -0.61% |
| Return on Capital (ROIC) | -62.45% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.11M |
| Employee Count | 5 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -41.1% in the last 52 weeks. The beta is 5.17, so Intensity Therapeutics's price volatility has been higher than the market average.
| Beta | 5.17 |
| 52-Week Price Change | -41.1% |
| 50-Day Moving Average | 2.19 |
| 200-Day Moving Average | 3.6 |
| Relative Strength Index (RSI) | 55.16 |
| Average Volume (20 Days) | 38.82K |
Income Statement
| Revenue | n/a |
| Gross Profit | -147K |
| Operating Income | -8.32M |
| Net Income | -10.54M |
| EBITDA | -10.09M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.38 |
Balance Sheet
The company has 8.56M in cash and 158K in debt, giving a net cash position of 8.4M.
| Cash & Cash Equivalents | 8.56M |
| Total Debt | 158K |
| Net Cash | 8.4M |
| Retained Earnings | -50.52M |
| Total Assets | 5.21M |
| Working Capital | 1.47M |
Cash Flow
In the last 12 months, operating cash flow was -7.21M and capital expenditures 0, giving a free cash flow of -7.21M.
| Operating Cash Flow | -7.21M |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.21M |
| FCF Per Share | -0.84 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
INTS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -58.72% |
| FCF Yield | -20.3% |
Analyst Forecast
The average price target for INTS is $8.5, which is 261.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.5 |
| Price Target Difference | 261.7% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -19.12 |
| Piotroski F-Score | 2 |